Debiopharm International SA, Lausanne, Switzerland
NARROW SPECTRUM FABI INHIBITOR
Direct-acting small molecule therapeutic
Debiopharm has discovered a new class of antibiotics that inhibit FabI, a bacterial fatty acid biosynthesis enzyme. FabI is essential in several bacterial species, including multi-drug resistant Acinetobacter baumannii, a rapidly emerging pathogen that causes infections including pneumonia, meningitis, urinary tract infection, and wound infection. The organism’s ability to survive under a range of environmental conditions and to persist for extended periods of time on surfaces make it a frequent cause of outbreaks of infection in health-care settings. People with weakened immune systems in hospital settings are particularly vulnerable. CARB-X funding will help support the development of a new molecular series with selective activity against A. baumannii FabI for nosocomial, or hospital acquired, pneumonia caused by this bacterium.
Current Development Stage: Lead Optimization
CARB-X Investment: Initial investment of up to $2.1m with potential option payments up to $1.6m.
Initial CARB-X Investment Date: March 1, 2019